Company Description
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Financials, Fundamental Metrics & Ratios
| Revenue (Most Recent Fiscal Year) |
$82.06B |
| Net Income (Most Recent Fiscal Year) |
$15.12B |
| PE Ratio (Current Year Earnings Estimate) |
18.37 |
| PE Ratio (Trailing 12 Months) |
15.88 |
| PEG Ratio (Long Term Growth Estimate) |
3.08 |
| Price to Sales Ratio (Trailing 12 Months) |
4.49 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) |
6.06 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) |
12.24 |
| Pre-Tax Margin (Trailing 12 Months) |
23.47% |
| Net Margin (Trailing 12 Months) |
24.47% |
| Return on Equity (Trailing 12 Months) |
39.71% |
| Return on Assets (Trailing 12 Months) |
15.27% |
| Current Ratio (Most Recent Fiscal Quarter) |
1.31 |
| Quick Ratio (Most Recent Fiscal Quarter) |
1.05 |
| Debt to Common Equity (Most Recent Fiscal Quarter) |
0.41 |
| Inventory Turnover (Trailing 12 Months) |
3.08 |
| Book Value per Share (Most Recent Fiscal Quarter) |
$22.60 |
| Earnings per Share (Most Recent Fiscal Quarter) |
$2.30 |
| Earnings per Share (Most Recent Fiscal Year) |
$8.68 |
| Diluted Earnings per Share (Trailing 12 Months) |
$7.56 |
